Circular Genomics
Albuquerque, US · Founded 2021 · Delaware corporation · 18 employees on LinkedIn · 5 known investors
Find your way into Circular Genomics
Sign up to see every warm intro you have to Circular Genomics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Circular Genomics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Circular Genomics develops a proprietary platform using circular RNA biomarkers to enable early detection and understanding of neurological diseases through blood tests. The company serves researchers, clinicians, and biopharma partners with diagnostic tools for conditions like Alzheimer's and Parkinson's.
Founders & leadership
Circular Genomics was founded in 2021 by Alexander Hafez.


Investors · 5
How we know: Cottonwood Technology Fund's portfolio page · a partner's Signal profile · funding news · innovations.unm.edu · the VCSheet dataset · Not right? Tell us
How we know: Mountain Group Capital's portfolio page · a partner's Signal profile · Not right? Tell us
Also in the syndicate · 2
Funding
SEC filings, press & company announcements$27.6M disclosed across 4 of 5 rounds · 2021–2025
- $15MSeries ADec 2025 · 3 sourcesSource ↗
▶$8.3MraisedJan 2024 · 9 investors · BiotechnologyRule 506(b)
- Fortunado RoccaDirector
- David BlivinDirector
- Paul SargeantExecutive Officer, Director
- Waneta TuttleDirector
- Nikolaos MelliosDirector
- Joseph Cook IIIDirector
- Offering amount
- $15M
- Amount sold
- $8.3M
- Minimum investment
- $100K
- First sale
- Jan 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$3.1MraisedMar 2023 · 7 investors · BiotechnologyRule 506(b)
- Stephen McKernanExecutive Officer
- Cathy PettiDirector
- Blivin DavidDirector
- Fortunado RoccaDirector
- Alexander HafezExecutive Officer, Director, Promoter
- Nikolaos MelliosExecutive Officer, Director, Promoter
- Paul SargeantExecutive Officer, Director
- Joseph Cook IIIDirector
- Waneta TuttleDirector
- Offering amount
- $3.2M
- Amount sold
- $3.1M
- Proceeds to insiders
- $850K
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.2MraisedAug 2021 · 7 investors · BiotechnologyRule 506(b)
- Alexander HafezExecutive Officer, Director, Promoter
- Nikolaos MelliosDirector, Promoter
- Offering amount
- $2M
- Amount sold
- $1.2M
- Proceeds to insiders
- $300K
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
Companies working in the same space as Circular Genomics.
In the news
Frequently asked questions
- What does Circular Genomics do?
- Circular Genomics develops a proprietary platform using circular RNA biomarkers to enable early detection and understanding of neurological diseases through blood tests. The company serves researchers, clinicians, and biopharma partners with diagnostic tools for conditions like Alzheimer's and Parkinson's.
- Who founded Circular Genomics?
- Circular Genomics was founded by Alexander Hafez in 2021.
- Who are Circular Genomics's investors?
- Circular Genomics's investors include Cottonwood Technology Fund, Mountain Group Capital, Tramway Venture Partners.
- How much funding has Circular Genomics raised?
- Circular Genomics has disclosed $27.6M raised across 4 of its 5 known rounds.
- Where is Circular Genomics headquartered?
- Circular Genomics is headquartered in Albuquerque, US.






